News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New TYSABRI® Analysis At American Academy of Neurology Annual Meeting Shows Improved Walking Speed In Significant Number Of MS Patients


5/1/2014 2:58:02 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Biogen Idec (NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES